The prognostic utility of the transcription factor SRF in docetaxel-resistant prostate cancer: in-vitro discovery and in-vivo validation

Table 1 List of predicted transcription factors (TFs) associated with docetaxel-resistance

Symbol of predicted target	Description	RefSeq Accession	Log (Fold Change)	P-Value
NFKB2	Nuclear factor of Kapa Light Polypeptide gene enhancer in B-cells 2	NM 002502	−0.769367	0.000829
SRF	c-fos serum response element-binding transcription factor	NM_003131	0.830936	0.000984
TR2	nuclear receptor subfamily 2, group C, member 1	NM_003297.3	0.93892	0.000149
TR4	nuclear receptor subfamily 2, group C, member 2	NM_003298.3	−2.117639	1.54E-05
NR1H2	nuclear receptor subfamily 1, group H, member 2	NM_007121	2.086756	1.36E-05
BRN5	POU domain, class 6, transcription factor 1	NM_002702.3	1.090898	0.011998
PPAR_RXR	peroxisome proliferator-activated receptor alpha	NM_001001928.2	−0.570508	0.025654
ER	estrogen receptor 1	NM_000125.3	1.7681357	8.57E-06
NFE2L2	nuclear factor (erythroid-derived 2)-like 2	NM_001145412.2	0.415401	0.010718

Transcriptomic data was integrated with known and predicted transcription factor binding sites (TFBS) resulting in a list of transcription factors (TFs) associated with the differential gene expression observed with the transcriptomic profiling

ISSN: 1471-2407